The WHO classification of lymphoid neoplasms represents a major step forward in our understanding of these tumors. Moreover, in building on the REAL classification, it has pointed the way to practical methods of further updating, which will be essential if the classification is to endure and to continue to serve the needs of clinicians. Implicit in the classification are signposts for further research, particularly with respect to DLBCL and T-cell lymphoma, unspecified. The formulation of the WHO classifications must be counted as a considerable achievement. By contrast with previous attempts to classify this difficult group of tumors, a large number of pathologists, 19 for the REAL classification and over 50 for the WHO scheme, have been involved, and to have achieved consensus within this group is remarkable! Perhaps even more remarkable is to have maintained this consensus in presenting such radically new concepts to the clinicians who treat patients with lymphoma.

8. Greiner TC, Medeiros LJ, Jaffe ES: Non-Hodgkin's lymphoma. Cancer 75:370-380, 1995.

9. Ko YH, Kim CW, Park CS, et al.: REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinico-pathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer 83:806-812, 1998.

10. Isaacson PG, Norton AJ: Extranodal lymphomas: malignant lymphoma of the gastrointestinal tract. In: Extranodal Lymphomas. Edinburgh: Churchill Livingstone; 1994:15-65.

11. Willemze R, Kerl H, Sterry W, et al.: EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 90:354-371, 1997.

12. Wright DH: Enteropathy associated T-cell lymphoma. Cancer Surv 30:249-261, 1997.

13. Isaacson PG: Primary splenic lymphoma. Cancer Surv 30:193-212, 1997.

14. Jaffe ES, Sander CA, Flaig MJ: Cutaneous lymphomas: a proposal for a unified approach to classification using the REAL/WHO Classification. Ann Oncol 11 (suppl 1): 17-21, 2000.

15. Campo E, Raffeld M, Jaffe ES: Mantle-cell lymphoma. Semin Hematol 36:115-127, 1999.

16. Jaffe ES: Angioimmunoblastic T-cell lymphoma: new insights, but the clinical challenge remains (editorial). Ann Oncol 6:631-632, 1995.

17. Kraut EH, Grever MR, Bouroncle BA: Long-term follow-up of patients with hairy cell leukaemia after treatment with 2'-deoxycoformycin. Blood 79:111-1120, 1994.

18. Brugieres L, Delay MC, Pacquement H, et al.: CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood 92:3591-3598, 1998.

19. Shipp MA: Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease? Blood 83:1165-1173, 1994.

20. Kuppers R, Rajewsky K, Zhao M, et al.: Hodgkin's disease: clonal Ig gene rearrangements in Hodgkin and Reed-Sternberg cells picked from histological sections. Ann N Y Acad Sci 764:523-524, 1995.

21. Marafioti T, Hummel M, Anagnostopoulos I, et al.: Origin of nodular lymphocyte-predominance Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med 337:453-458, 1997.

22. Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89:3909-3918, 1997.

23. Ashton-Key M, Thorpe PA, Allen JP, et al.: Follicular Hodgkin's disease. Am J Surg Pathol 19:1294-1299, 1995.

24. Staudt LM: Gene expression profiling of lymphoid malignancies. Annu Rev Med 53:303-318, 2002.

25. Willemze R, Meijer CJLM, Sentis HJ, et al.: Primary cutaneous large cell lymphomas of follicular center cell origin. J Am Acad Dermatol 16:518-526, 1987.

26. Coiffier B, Anderson J, Armitage J, et al.: Clinical prognostic factors are stronger predictors of outcome in non-Hodgkin's lymphoma (NHL) than pathologic subtype. Blood 88:293a, 1996.

27. Harris NL, Jaffe ES, Diebold J, et al.: Lymphoma Classification-from controversy to consensus: the REAL and WHO Classification of lymphoid neoplasms. Ann Oncol 11(suppl 1):3-10, 2000.

28. Mann R, Berard C: Criteria for the cytologic subclassification of follicular lymphomas: a proposed alternative method. Hematol Oncol 1:187-192, 1982.

29. Martin AR, Weisenberger DD, Chan WC, et al.: Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood 85:3671-3678, 1995.

30. Isaacson PG: Extranodal lymphomas: the MALT concept. Verh Dtsch Ges Pathol 76:14-23, 1992.

31. Nizze H, Cogliatti SB, von Schilling C, et al.: Monocytoid B-cell lymphoma: morphological variants and relationship to low grade B-cell lymphoma of the mucosa-associated lymphoid tissue. Histopahtology 18:403-414, 1991.

32. Mollejo M, Menarguez J, Lloret E, et al.: Splenic marginal zone lymphoma: a distinctive type of low-grade B-cell lymphoma. A clinicopathological study of 13 cases. Am J Surg Pathol 19:1146-1157, 1995.

33. Catovsky D, Matutes E: Splenic lymphoma with circulating villous lymphocytes/splenic marginal zone lymphoma. Semin Hematol 36:148-154, 1999.

34. Catovsky D: Current approach to the biology and treatment of chronic lymphoid malignancies other than CLL. Hematol Cell Ther 38:S63-S66, 1996.

35. Aisenberg AC: Primary large cell lymphoma of the mediastinum. Semin Oncol 26:251-258, 1999.

36. Alizadeh AA, Eisen MB, Davis RE, et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511, 2000.

37. Rosenwald A, Wright G, Chan WC, et al.: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346: 1937-1947, 2002.

38. Falini B, Bigerna B, Fizzotti M, et al.: ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. Am J Pathol 53:875-886, 1998.

39. Paulli M, Berti E, Rosso R, et al.: CD30/Ki-1 positive lymphoproliferative disorders of the skin. Clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the EORTC cutaneous lymphoma project group. J Clin Oncol 13: 1343-1354, 1996.

40. Willemze R, Beljaards RC: Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment. J Am Acad Dermatol 28:973-980, 1993.

This page intentionally left blank

Chapter 52

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment